Dupuytren's Disease

Definition

Dupuytren's disease is a benign fibroproliferative disorder affecting the palmar and digital fascia, resulting in progressive nodule and cord formation with flexion contracture of the digits. Named after Baron Guillaume Dupuytren who described surgical treatment in 1831.

View larger

Epidemiology

Population Prevalence:

• Western/European-ancestry pooled means: 12% (age 55), 21% (age 65), 29% (age 75)
• Northern European descent: up to 30% in men over 60
• Markedly lower in African, East Asian and South Asian populations
• Increases dramatically with age after 50 years

Demographics:

• Gender: Male to female ratio 7:1 in younger patients, equalizes after age 70
• Age: Peak presentation 50-60 years, can occur younger with diathesis
• Laterality: Right hand slightly more common, 40-60% bilateral
• Digit distribution: Ring greater than little greater than middle greater than index greater than thumb

Associated Risk Factors (DASHED):

• Diabetes mellitus: 20% prevalence (vs 4% general population)
• Alcohol consumption: Dose-dependent association, hepatic fibrosis link
• Smoking: 2-3x increased risk via microvascular effects
• Hereditary/Northern European: Strongest predictor, autosomal dominant pattern
• Epilepsy medications: Phenytoin, phenobarbital association
• Disease associations: Peyronie (penile), Ledderhose (plantar), Garrod pads (knuckles)

Dupuytren's Diathesis

Describes aggressive disease phenotype with poor prognosis:

• Young onset (less than 40 years)
• Bilateral hand involvement
• Ectopic fibromatoses (Peyronie, Ledderhose)
• Strong family history
• Radial side involvement (index, middle, thumb)
• Dorsal Garrod pads

Diathesis patients have higher recurrence rates (up to 70% at 5 years) and may benefit from more aggressive initial surgery (dermofasciectomy).

Cellular and Molecular Basis

The Myofibroblast is the central pathological cell in Dupuytren's disease:

• Modified fibroblast with smooth muscle-like contractile apparatus
• Contains alpha-smooth muscle actin (alpha-SMA) stress fibers
• Produces excessive Type III collagen (vs Type I in normal fascia)
• Generates contractile force via actin-myosin interaction
• Responds to TGF-beta and mechanical stress signals

Molecular Pathways:

• TGF-beta signaling: Central driver of myofibroblast differentiation
• Wnt pathway: Promotes fibroblast to myofibroblast transformation
• Mechanical stress: Tension induces myofibroblast activation
• Hypoxia: Local tissue hypoxia may trigger fibrogenesis
• Free radicals: Oxidative stress in pathological tissue

Three Phase Disease Progression

Phase 1 - Proliferative:

• Active myofibroblast proliferation
• High cellularity with immature fibroblasts
• Nodule formation in palm and digits
• Type III collagen predominates
• May be painful, progressive

Phase 2 - Involutional:

• Myofibroblast alignment along stress lines
• Cord formation from palmar nodules extending to digits
• Contracture begins and progresses
• Transition from Type III to Type I collagen
• Less cellular, more organized collagen

Phase 3 - Residual:

• Mature, relatively acellular cord
• Dense Type I collagen bundles
• Established fixed contracture
• Minimal active disease
• Low recurrence risk if excised

Normal Palmar Fascial Anatomy

Longitudinal Components:

• Pretendinous bands: Four bands from palmaris longus to digits (ring and little most prominent)
• Natatory ligament: Connects pretendinous bands distally
• Spiral band: From natatory to lateral digital sheet

Transverse Components:

• Transverse palmar ligament: At MCP level
• Natatory ligament: Distal palm between web spaces

Vertical Components:

• Septa of Legueu and Juvara: Anchor fascia to skeleton
• Eight vertical septa create palmar compartments

Digital Fascia:

• Lateral digital sheet: Lateral to flexor sheath
• Grayson ligament: Volar to neurovascular bundle
• Cleland ligament: Dorsal to neurovascular bundle (not involved in Dupuytren's)

Four Major Cord Types

1. Pretendinous Cord (Most Common)

• From pretendinous band in palm
• Extends from distal palmar crease to base of digit
• Causes MCP joint contracture
• Neurovascular bundle remains in normal position
• Relatively safe to excise

2. Central Cord

• Continuation of pretendinous cord into digit
• Lies central in digit over flexor sheath
• Causes PIP joint contracture
• Neurovascular bundle in normal position
• Common in ring and little fingers

3. Spiral Cord (Most Dangerous)

• Four components (PSLG):
  1. Pretendinous band (palm)
  2. Spiral band (from natatory ligament)
  3. Lateral digital sheet (lateral to flexor sheath)
  4. Grayson ligament (volar to NV bundle)
• Spirals around and displaces NV bundle centrally and superficially
• NV bundle can be displaced up to 1cm from normal position
• Highest risk of iatrogenic nerve injury
• Requires careful dissection under loupe magnification

4. Lateral Cord

• From lateral digital sheet alone
• Causes PIP joint contracture
• Less common than other types
• NV bundle usually in normal position

5. Other Rare Cords:

• Retrovascular cord: Dorsal to NV bundle (very rare)
• Natatory cord: In web space, causes web space contracture
• Thumb cords: First web pretendinous, proximal commissural

View larger

View larger

History

Chief Complaint:

• Progressive inability to fully extend fingers
• Difficulty placing hand flat on surfaces
• Functional impairment: hand hygiene, glove wearing, placing hand in pocket
• Usually painless (pain suggests active proliferative phase)

Timeline:

• Insidious onset, progressive over months to years
• May notice palmar nodule before contracture develops
• Periods of rapid progression alternating with stability

Functional Impact:

• Difficulty with fine motor tasks
• Problems with gripping tools/objects
• Cosmetic concerns
• Interference with occupation

Risk Factor Assessment:

• Ancestry (Northern European/Celtic)
• Diabetes status and control
• Alcohol consumption history
• Epilepsy medication use
• Family history of Dupuytren's
• Bilateral hand involvement
• Ectopic fibromatoses (Peyronie, Ledderhose, Garrod pads)

View larger

Examination

Inspection:

• Palmar nodules: Firm, subcutaneous, adherent to skin
• Skin pitting: Overlying involved cords
• Cords: Palpable longitudinal bands from palm to digits
• Contracture: Flexion deformity at MCP and/or PIP joints
• Digit distribution: Record which rays involved
• Skin condition: Check for previous surgical scars, skin quality

Palpation:

• Identify nodules and cords
• Distinguish from flexor tendons (cords don't move with finger flexion)
• Check consistency (hard mature cord vs soft nodule)
• Skin adherence and pitting

Contracture Measurement:

• MCP contracture: Measure with goniometer, record separately
• PIP contracture: Measure separately (most important for prognosis)
• Total passive extension deficit (TPED): Sum of all joint contractures
• Active vs passive: Document both (rule out joint pathology)

Table-Top Test (Hueston Test):

• Patient attempts to place palm flat on table surface
• Positive: Cannot achieve flat palm-to-table contact
• Indicates functionally significant contracture
• Traditional threshold for surgical intervention

Neurovascular Assessment:

• Digital sensation (light touch, 2-point discrimination)
• Capillary refill and color
• Allen test if vascular concern
• Document baseline before any intervention

Bilateral Assessment:

• Always examine both hands
• 40-60% have bilateral involvement
• May be asymmetric in severity

Diathesis Features:

• Age at onset (less than 40 years concerning)
• Garrod pads (dorsal PIP knuckle pads)
• Ectopic disease: Peyronie (penile), Ledderhose (plantar)
• Family history

Differential Diagnosis

Blood Tests

Screening for Risk Factors:

• HbA1c or fasting glucose: Screen for diabetes if not known
• Liver function tests: If alcohol history suggests hepatic disease
• No specific blood test for Dupuytren's disease

Imaging

Radiographs (X-rays):

• Not routinely indicated for primary diagnosis
• Consider if joint pathology suspected (arthritis, previous fracture)
• Pre-operative in severe contractures to assess joint integrity
• Fixed PIP contracture: X-ray to check for secondary joint changes

Ultrasound:

• High-resolution ultrasound can demonstrate:
  • Thickened palmar fascia
  • Cord identification and extent
  • Relationship to neurovascular structures
• Mainly research tool, not routine clinical practice
• May help distinguish Dupuytren's from other masses

MRI:

• Rarely indicated in primary disease
• Useful for complex cases or diagnostic uncertainty
• Can show:
  • Full extent of fascial involvement
  • Relationship to tendons, NV bundles, joints
  • Secondary joint pathology
• T1: Low signal cords
• T2: Variable signal depending on cellularity/phase

Histopathology

Not required for diagnosis but if tissue obtained shows:

• Myofibroblasts with alpha-SMA immunostaining
• Type III collagen predominance (early)
• Transition to Type I collagen (late)
• Variable cellularity depending on phase
• No malignant features (benign process)

Pre-operative Assessment

Before Surgery:

• Document baseline contractures with goniometry
• Photograph hand
• Assess neurovascular status
• X-ray if severe PIP contracture or trauma history
• Optimize diabetes control if present
• Smoking cessation counseling

Algorithm

View larger

Conservative Management

Observation:

• Indications: Nodules without contracture, minimal contracture (less than 30° MCP, no PIP)
• Monitor progression every 6-12 months
• Patient education about disease natural history
• No proven method to prevent progression

Intralesional Corticosteroid Injection:

• May reduce nodule size in early disease
• Triamcinolone 10-40mg injected directly into nodule
• Evidence limited to case series
• Can cause fat pad atrophy and skin depigmentation
• Not effective for established cords

View larger

Radiotherapy:

• Low-dose radiation (superficial X-ray or electron beam)
• May slow progression in early nodular phase
• Evidence limited, not standard of care
• Used in parts of Europe (notably Germany); not widely adopted elsewhere
• Concerns about long-term radiation effects

Splinting:

• No role in preventing contracture progression
• May worsen disease via mechanical stress
• Post-operative extension splinting has role (see post-op care)

Non-Surgical Interventional Management

CollagenaseNeedle Aponeurotomy

Collagenase Injection (Xiaflex)

Mechanism:

• Clostridium histolyticum collagenase
• Enzymatic breakdown of Type I and III collagen in cord
• Weakens cord allowing manipulation and rupture

Technique:

• Inject 0.58mg into palpable cord
• For MCP: Inject at distal palmar crease level
• For PIP: Inject at base/mid-proximal phalanx
• Patient returns next day (24-48 hours)
• Manipulation to rupture cord under local anesthetic
• Extension splinting for 4 months post-procedure

View larger

Indications:

• MCP contracture with palpable cord
• Single joint involvement preferred
• Patient preference for non-surgical option
• Comorbidity precluding surgery

Contraindications:

• Allergy to collagenase
• Anticoagulation (relative)
• Multiple joints in same finger (can treat sequentially)

Outcomes:

• Success rate: 60-70% achieve less than 5° contracture
• MCP joints: Better response than PIP
• Recurrence: Similar to needle aponeurotomy (approximately 50% at 5 years)

Complications:

• Skin tears (common, usually heal)
• Bruising, swelling, pain
• Lymphadenopathy
• Tendon rupture (rare but reported - flexor tendon)
• Allergic reaction
• CRPS (rare)

Global Availability:

• Region-dependent: FDA-approved in the US; withdrawn from UK/EU markets in 2020 for commercial reasons despite retained efficacy
• Where unavailable, needle fasciotomy fills the minimally invasive niche
• Cost remains a major access barrier in many health systems

This treatment option is appropriate for the non-surgical patient.

Percutaneous Needle Aponeurotomy (NA)

Technique:

• Percutaneous division of cord using hypodermic needle (25G)
• Multiple passes to weaken and divide cord
• Perform under local anesthetic in office/clinic
• Manipulation after cord division
• Extension splinting post-procedure

Indications:

• Elderly patients, significant comorbidity
• MCP contractures (better than PIP)
• Patient preference for minimally invasive
• Recurrent disease (can repeat)

Contraindications:

• Spiral cord (risk of NV injury)
• Severe PIP contracture
• Skin condition poor
• Anticoagulation (relative)

Advantages:

• Office procedure
• Rapid recovery (days not weeks)
• Can repeat if recurs
• Low complication rate
• Cost-effective

Disadvantages:

• High recurrence rate: 50-60% at 3-5 years
• Less effective for PIP than MCP
• Cannot address skin deficiency
• Risk of NV injury if spiral cord
• Skin tears possible

Outcomes:

• Immediate correction: 80-90% achieve less than 10° extension deficit
• Long-term: Approximately 50% recurrence at 5 years
• Better for MCP than PIP contractures
• Satisfaction high despite recurrence (can repeat)

Complications:

• Skin tears (5-10%)
• Digital nerve injury (less than 1%)
• Tendon injury (rare)
• Infection (rare)

Excellent option for elderly with MCP disease who want quick return to function.

Immediate Post-operative (0-2 weeks)

Dressing:

• Bulky dressing with extension splint
• Elevate hand (reduce edema)
• Monitor neurovascular status
• Pain control (oral analgesia usually sufficient)

Wound Care:

• Dressing change at 2-3 days if excessive drainage
• Leave wounds open OR remove sutures at 2 weeks
• Open palm technique: regular dressings until healed (4-6 weeks)

Early Mobilization:

• Start day 1-2 post-operatively
• Active flexion exercises to prevent stiffness
• Gentle extension (don't force)
• Critical for outcome

Rehabilitation Phase (2-12 weeks)

Hand Therapy:

• Essential component of treatment
• Active range of motion exercises
• Scar massage (once wounds healed)
• Edema control (compression, elevation)
• Strengthening exercises (progressive)

Splinting:

• Extension splinting at night: 3-6 months
• Maintains correction while healing
• Evidence for reducing recurrence unclear but commonly practiced
• Custom thermoplastic splint

Return to Activities:

• Light activities: 2-4 weeks
• Heavy activities: 6-12 weeks
• Individualize based on occupation, healing

Long-term Follow-up

Monitoring:

• 6 weeks, 3 months, 6 months, 12 months post-op
• Assess range of motion, scar, function
• Monitor for recurrence (distinguish from extension)
• Patient education about recurrence risk

Outcomes:

• Full outcome assessment at 12 months
• MCP contractures: Excellent correction, low recurrence
• PIP contractures: More variable correction, higher recurrence
• Patient satisfaction generally high despite recurrence risk

Global Epidemiology

• Western/European-ancestry meta-analysis: mean prevalence 12% at age 55, 21% at 65, 29% at 75 (Lanting 2014)
• Highest rates in Scandinavian/Celtic populations; Norwegian men over 60 up to 30%
• Markedly lower in African, East Asian and South Asian populations
• Male predominance (up to 7:1 in younger cohorts), narrowing with age

Side-by-Side Guidance

Note: collagenase clostridium histolyticum (Xiapex/Xiaflex) was withdrawn from several markets including the UK and EU in 2020 for commercial reasons, despite retained efficacy — availability is now region-dependent.

Registry and Outcome Notes

• No dedicated international Dupuytren implant registry exists (no implant involved)
• Best comparative long-term data come from RCTs (van Rijssen) and pharmacovigilance cohorts (CORDLESS)
• National hand-surgery audits increasingly track recurrence using the Felici per-joint definition

High- vs Limited-Resource Practice

• Well-resourced settings: full menu — needle fasciotomy, collagenase (where available), limited fasciectomy, dermofasciectomy, hand-therapy-led rehabilitation
• Limited-resource settings: open fasciectomy under regional/local anaesthesia is the mainstay; collagenase often unavailable due to cost; emphasis on single definitive procedure
• Constitutional, not occupational: generally regarded as a heritable/constitutional disease; heavy manual vibration exposure is at most a weak contributory factor